Alnylam Pharma: Health Canada Grants Priority Review To Patisiran - Quick Facts

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced that Health Canada has granted Priority Review status to patisiran. The company said the regulatory submission in Canada for the treatment of patients with hATTR amyloidosis will be based on data from the APOLLO Phase 3 study. The randomized, double-blind, placebo-controlled, global Phase 3 is the largest-ever study conducted in hATTR amyloidosis patients with polyneuropathy, and enrolled patients in Canada.

"We look forward to continuing to work closely with Health Canada during the review process," said Jeff Miller, Country Manager, Alnylam Canada.